• Alias: MK-4827
    • An inhibitor of PARP-1 and -2
    • FDA approved for recurrent epithelial ovarian cancer, fallopian tube or primary peritoneal cancer patients who are in complete or partial response to platinum-based chemotherapy
    • Recommended dose: 300 mg PO daily with or without food
    • Median terminal half-life: 36 hours (range 33–46 hours)
    • Metabolism: CYP1A2 and CYP3A4; P-glycoprotein
    • Common side effects: Fatigue, insomnia, pneumonitis, anorexia, constipation, nausea/vomiting, neutropenia, thrombocytopenia
    Other topics in Targeted and Immunotherapy Agents